{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:49:59Z","timestamp":1770392999352,"version":"3.49.0"},"reference-count":23,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novo Nordisk","award":["2025-34"],"award-info":[{"award-number":["2025-34"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Patient Support Programs (PSPs) are increasingly used to support treatment adherence and continuity of care in chronic, high-cost conditions. In hemophilia A, consistent prophylaxis is essential to prevent bleeding episodes and long-term joint damage. In Mexico, disparities in access to treatment have encouraged the development of public\u2013industry collaborative models. The objective of this study was to describe the structure, implementation, and operational characteristics of a PSP delivering home-based prophylactic treatment for individuals with hemophilia A in Mexico, and to compare annual bleeding rates according to factor VIII dosing adequacy. Methods: A cross-sectional, retrospective analysis was conducted using fully anonymized operational data from the PSP registry between January 2023 and March 2024. Variables included infusion location and administrator, prescribed and used doses, weekly infusion frequency, program incorporation and discontinuation, geographic coverage, and bleeding events. Annual bleeding rates were compared across dosing categories using Poisson regression models with patient-years as an offset. Results: A total of 1173 patients contributed 16,331 infusion records. Participants were predominantly male (99.8%), with a median age of 26 years; 71.8% had severe hemophilia. Home infusion accounted for 92.0% of administrations, primarily self-administered or caregiver-delivered. The median prescribed and used monthly doses were 18,000 IU and 16,000 IU, respectively, with dose concordance observed in 66.8% of records. Only 40.7% of patients achieved the recommended prophylactic frequency of three infusions per week. Geographic coverage increased from 62.5% to 71.9% of states. The overall annualized bleeding rate was 2.24 bleeds per patient-year. When stratified by dosing adequacy, patients receiving doses consistent with clinical recommendations showed the lowest bleeding rate (0.18 bleeds per patient-year), compared with those with overdosing (3.84) and underdosing (6.68), with statistically significant differences between groups. Knees, elbows, and ankles were the most frequently affected sites. Conclusions: This PSP achieved broad national reach and high adoption of home-based infusion. The observed dose-dependent differences in bleeding rates underscore the clinical relevance of appropriate prophylactic dosing within structured support programs and support the value of PSPs in strengthening treatment continuity in middle-income settings.<\/jats:p>","DOI":"10.3390\/jcm15031217","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:51:56Z","timestamp":1770209516000},"page":"1217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Hemophilia A Care Through Home-Based Prophylaxis: Real-World Outcomes of a National Patient Support Program in Mexico"],"prefix":"10.3390","volume":"15","author":[{"given":"Israel","family":"Rico-Alba","sequence":"first","affiliation":[{"name":"Novo Nordisk, Mexico City 11560, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1827-0218","authenticated-orcid":false,"given":"Alberto Retana","family":"Guzm\u00e1n","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Mexico City 11560, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Marquez-Gonzalez","sequence":"additional","affiliation":[{"name":"Epidemiological Research Unit, Hospital Infantil de M\u00e9xico Federico G\u00f3mez, Ministry of Health (SSA), Mexico City 06720, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-7964","authenticated-orcid":false,"given":"Jessie Nallely","family":"Zurita-Cruz","sequence":"additional","affiliation":[{"name":"Facultad de Medicina, Universidad Nacional Aut\u00f3noma de Mexico, Hospital Infantil de Mexico Federico G\u00f3mez, Mexico City 06720, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"ref_1","unstructured":"Instituto Mexicano del Seguro Social (2025, December 15). Gu\u00eda de Pr\u00e1ctica Cl\u00ednica: Diagn\u00f3stico y Tratamiento de la Hemofilia Hereditaria en el Ni\u00f1o y en el Adulto (IMSS-141\u201418). Available online: https:\/\/www.imss.gob.mx\/node\/85190."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: Updated review of evidence and treatment guidance","volume":"92","author":"Kempton","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_3","first-page":"S1","article-title":"Consensus on hemophilia in Mexico","volume":"157","year":"2021","journal-title":"Gac. Med. Mex."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2277497","DOI":"10.1080\/16078454.2023.2277497","article-title":"Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India","volume":"28","author":"Seth","year":"2023","journal-title":"Hematology"},{"key":"ref_5","first-page":"290","article-title":"An\u00e1lisis del costo y la efectividad de los esquemas de administraci\u00f3n de factores de coagulaci\u00f3n en ni\u00f1os con hemofilia A en M\u00e9xico","volume":"70","author":"Rely","year":"2013","journal-title":"Bol. Med. Hosp. Infant. Mex."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40271-022-00582-y","article-title":"The Impact of Patient Support Programs in Europe: A Systematic Literature Review","volume":"15","author":"Artime","year":"2022","journal-title":"Patient"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2057831","DOI":"10.1080\/23288604.2022.2057831","article-title":"Commercial and Social Value of Pharmaceutical Industry-led Access Programs: Conceptual Framework and Descriptive Analysis","volume":"8","author":"Heerdegen","year":"2022","journal-title":"Health Syst. Reform"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1055\/s-0043-1778103","article-title":"Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment","volume":"50","author":"Chandran","year":"2024","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2010.029868","article-title":"A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A","volume":"96","author":"Fischer","year":"2011","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2200072","DOI":"10.9745\/GHSP-D-22-00072","article-title":"Digital Health Technologies Applied by the Pharmaceutical Industry to Improve Access to Noncommunicable Disease Care in Low- and Middle-Income Countries","volume":"10","author":"Heerdegen","year":"2022","journal-title":"Glob. Health Sci. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"Berntorp","year":"2012","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/hae.12731","article-title":"Assessments of outcome in haemophilia\u2014What is the added value of QoL tools?","volume":"21","author":"Feldman","year":"2015","journal-title":"Haemophilia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1007\/s00277-020-04250-9","article-title":"Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting","volume":"99","author":"Ay","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/JBM.S363028","article-title":"The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study","volume":"13","author":"Grazzi","year":"2022","journal-title":"J. Blood Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Abshire","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"103736","DOI":"10.1016\/j.htct.2025.103736","article-title":"Annualized bleeding rate in hemophilia A patients in Brazil: A systematic review","volume":"47","author":"Prezotti","year":"2025","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_18","first-page":"264","article-title":"Prophylaxis in hemophilia: Situation analysis and call-to-action in Latin America. A report from the GLAITH group","volume":"56","author":"Mijares","year":"2015","journal-title":"Investig. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1365-2516.2003.00853.x","article-title":"Home management of haemophilia","volume":"10","author":"Teitel","year":"2004","journal-title":"Haemophilia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/PPA.S139851","article-title":"Treatment adherence in hemophilia","volume":"11","author":"Thornburg","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mokhtar, F.M., Sathar, J., and Huri, H.Z. (2021). Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention. Healthcare, 9.","DOI":"10.3390\/healthcare9121702"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/joah.joah_45_23","article-title":"The home care delivery program in hemophilia: Adescriptive Italian multicentric study on patients, caregivers, and clinicians\u2019 points of view","volume":"14","author":"Porreca","year":"2023","journal-title":"J. Appl. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1111\/hae.12951","article-title":"Predictors of non-adherence to prescribed prophylactic clotting-factor treatment regimens among adolescent and young adults with a bleeding disorder","volume":"22","author":"Witkop","year":"2016","journal-title":"Haemophilia"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:17:54Z","timestamp":1770355074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031217"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031217","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}